What is the efficacy of azacitidine for the treatment of acute myeloid leukemia (AML) in older patients?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

A randomized, open-label, phase III trial in 488 patients age ≥65 years with newly diagnosed AML with > 30% bone marrow blasts reported a 1-year survival rate of 46.5% with azacitidine versus 34.2% with conventional care regimens. [66] In a study of azacitidine treatment in 130 AML patients older than 50 years (median age, 67 years) who had experienced relapse or induction failure with intensive chemotherapy, the overall response rate was 17% (complete response [CR], 10%, CR with incomplete platelet or neutrophil count recovery [CRi], 7%). [67]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!